Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab
Clinical trial NCT05744375 · TERMINATED
Trial details
- NCT number
- NCT05744375
- Sponsor
- Spanish Breast Cancer Research Group
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-09-28
- Primary completion
- 2025-07-17
- Enrollment
- 2
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.